Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704116 | 0.87 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL4704535 | 0.84 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL14051588 | 0.84 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL14605599 | 0.84 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL13964181 | 0.83 | CYP3A4 (0.79) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL4704791 | 0.83 | CYP2C9 (0.71) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL4702288 | 0.83 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL4704222 | 0.83 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL4704510 | 0.83 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL4704204 | 0.82 | CYP3A4 (0.77) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506195-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1506195-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-6806265-B2 | FOR THERAPY AND PROPHYLAXIS OF HIV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-19 | — | — | US | disclosed |
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2004-01-08 | — | — | US | disclosed |
| WO-2003097644-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | CBR1, POLR2H, SUB1 | CYP3A4 257/4885CYP2C9 778/4885CYP2C19 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.